The Wall Street Journal reports that representatives of Novo Nordisk (NVO.US) and maker of Ozempic and Wegova, as well as its rival Eli Lilly (LLY.US), which makes anti-obesity drugs Zepbound and Mounjaro, are visiting US unions and HR teams in private companies, to make the case for implementing GLP-1 anti-obesity treatments, potentially improving sales and US market interest.
- According to consulting firm Leverage, about 25% or 65 million Americans have a health insurance plan that covers weight-loss drugs. Some 44% of U.S. employers with at least 500 employees offered health insurance extended to weight-loss drugs in 2024. So the market likes the 'proactive' activity from representatives of the two pharmaceutical giants.
- The drugs mimic the hormone that regulates appetite and blood sugar levels, and have become highly sought after for treating obesity and type 2 diabetes. Morgan Stanley estimates that the market for GLP-1 drugs will reach $105 billion by 2030, although this will depend on availability to patients. So far, US employers have been reluctant to cover the cost of obesity drug treatments.
- Currently, the Wegovy app costs $1,350 per month, and the Zepbound price is about $1,060 per month. Manufacturers emphasize that the fight against obesity and its related complications can lead to long-term savings in health care costs for employers.
- This year, the U.S. Food and Drug Administration approved Novo Nordisk's drug Wegovy to reduce the risk of heart disease. Eli Lilly is seeking approval for the drug Zepbound to treat sleep apnea. In addition, a number of studies suggest that the drugs can help with a number of conditions including addiction treatment and Alzheimer's disease. The recent market reaction was driven by broader
Eli Lilly and Novo Nordisk chart
Eli Lilly and Novo Nordisk shares are trading about 10% below the exponential average of the EMA200 (red line), which has historically been an accumulation opportunity for long-term investors. A sizable risk is the possible tightening of regulations on GLP-1 applications under the Donald Trump administration. The outlook for anti-obesity drugs has pushed the premium in the valuation of both companies to record levels.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appSource: xStation5
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
